ISTA Pharmaceuticals releases preliminary results from phase II/III study of bepotastine

ISTA Pharmaceuticals Inc. announced results from the preliminary analysis of its phase II/III clinical study of bepotastine for the treatment of allergic conjunctivitis. The study evaluated two concentrations of bepotastine, each dosed once daily and twice daily.

Related Videos
View All
Related Content
© 2023 MJH Life Sciences

All rights reserved.